Skip to main content
Conference Insider

JAK-STAT and the Future of Autoimmune Diseases

The development of Janus kinase (JAK) inhibitors has opened a world of possibilities for the treatment of various immune-mediated inflammatory conditions, including psoriasis and sarcoidosis. In a lecture on JAK inhibitors, Vibeke Strand, MD, reviewed the latest evidence on approved and in development therapies.

 

While JAK inhibitors display different in vitro profiles, clinical responses to JAK inhibitors appear to be similar, said Dr Strand.

 

Several JAKs are in development for rheumatoid arthritis, psoriatic arthritis, spondyloarthropathy, and juvenile inflammatory arthritis, including tofacitinib, baricitinib, upadacitinib, filgotinib. The EQUATOR showed positive results with the high dose of filgotinib among patients with rheumatoid arthritis. In dermatology, Dr Strand stated, several JAK inhibitors show dramatic differences in patients. Phase 2 trials showed improvements in atopic dermatitis with tofacitinib and upadacitinib, and alopecia areata with tofacitinib. Similar studies showed high doses of JAK inhibitors improved psoriasis. In addition, a case report showed a patient with sarcoidosis treated with tofacitinib achieved clinical remission, said Dr Strand.

 

For inflammatory bowel diseases, tofacitinib was not found to be effective for patients with Crohn disease, but was approved by the FDA for ulcerative colitis at the 5 mg and 10 mg doses. Case reports showed patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures were effectively treated with the JAK inhibitors tofacitinib and ruxolitinib. Other autoimmune conditions covered in Dr Strand’s presentation included systemic lupus, primary Sjogren’s syndrome, dermatomyositis, and giant cell arteritis.  

 

Safety data is primary from extensive clinical development programs in rheumatoid arthritis. The safety profile is similar to tumor necrosis factor inhibitors, said Dr Strand, with major concerns for serious infections, herpes zoster reactivation, and malignancies, as well as lab abnormalities.

 

New safety data showed an increased risk for pulmonary embolism and thromboembolism among patients with RA treated with JAK inhibitors. However, patients with RA have an increased risk of these events, said Dr Strand. Thus, more studies are needed to determine whether these are associated with the therapies or with patients’ underlying disease.

 

JAK inhibitors are effective for several autoimmune diseases, including some with few therapeutic approved options.

 

Reference

Strand V. Exploring the role of JAK inhibitors across the spectrum of IMIDs. Presented at: 2019 Interdisciplinary Autoimmune Network; April 5-7, 2019; Chicago, IL.